Navigation Links
MidCap Financial Launches Commercial Finance Company With Over $500 Million of Equity
Date:11/25/2008

BETHESDA, Md., Nov. 25 /PRNewswire/ -- MidCap Financial LLC, a new commercial finance company that will focus on middle market lending to the healthcare industry, today announced its formation and funding with over $500 million in equity commitments. MidCap's investors are Thomas H. Lee's Lee Equity Partners LLC, Genstar Capital LLC and Moelis Capital Partners. MidCap also has a substantial long-term debt facility in place, led by Wells Fargo Foothill, part of Wells Fargo & Company (NYSE: WFC).

MidCap is being led by the entire former senior management team of Merrill Lynch Capital Healthcare Finance, including its founder, Howard Widra, who will serve as Chief Executive Officer of MidCap. Prior to founding Merrill Lynch Capital Healthcare Finance, Mr. Widra served as President of GE Healthcare Financial Services, President of Heller Healthcare Finance, and Chief Operating Officer of Healthcare Financial Partners.

The other senior members of MidCap's management team include:

-- Steve Curwin, Chief Credit Officer, who formerly served as Managing Director and Chief Credit Officer of ML Capital Healthcare Finance;

-- David Moore, Chief Financial Officer and Chief Administrative Officer, who formerly served as Managing Director and Head of ML Capital Healthcare Finance's asset-based lending business;

-- Kevin McMeen, Head of Real Estate Finance, who formerly served as Managing Director and Head of ML Capital Healthcare Finance's real estate business;

-- Clare Bailhe, Head of Leveraged Finance, who formerly served as Managing Director and Head of ML Capital Healthcare Finance's leveraged loan business; and

-- Will Gould, Head of Life Sciences and Asset Based Lending, who founded and served as Head of ML Capital Healthcare Finance's life sciences business
'/>"/>

SOURCE MidCap Financial LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Smart Balance Presented at Citi Small/Midcap Conference
2. Smart Balance to Webcast Presentation at Citi Small/Midcap Conference
3. HMS Holdings Corp. to Present at Bank of America 2008 SmidCap Conference
4. A.M. Best Affirms Regences Solid Financial Position
5. New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes
6. SEIUs Andy Stern Renews Call to Fix Nations Broken Health Care System, Ease Financial Strain on Working Families, Economy
7. Streamline Health to Announce Third Quarter of Fiscal Year 2008 Financial Results on Tuesday, December 2, 2008
8. Blue Cross Blue Shield of Michigan Calls for Attorney General to Support Stronger Regulation of Commercial Insurers; Protections for Consumers; and Financially Stable Insurance Market
9. Pregis Announces Third Quarter 2008 Financial Results
10. PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
11. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 1Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 1ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 3ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 4ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 5ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 6ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 7ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 8ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 9ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 10ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 11